Cell Source, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020
April 15, 2021 at 06:03 am
Share
Cell Source, Inc. announced earnings results for the full year ended December 31, 2020. For the full year, the company announced operating loss was USD 3.638 million compared to USD 3.805 million a year ago. Net loss was USD 4.560 million compared to USD 4.475 million a year ago. Basic loss per share from continuing operations was USD 0.19 compared to USD 0.18 a year ago.
Cell Source, Inc. is a cell therapy company focused on immunotherapy. The Company is primarily focused on the development of immune system management technology (Veto Cell technology). Its lead prospective product is its Veto Cell immune system management technology. Its Veto Cell technology is an immune tolerance biotechnology that enables the selective blocking of immune responses. Its Veto Cell technology is in pre-clinical phase, and its data shows that it provides results in allogeneic (donor-derived) hematopoietic stem cell transplantation (HSCT) by allowing for haploidentical stem cell transplants under a mild conditioning regimen. Its product pipeline includes chimeric antigen receptor (CAR) T-cell therapies, which include VETO CAR-T (with or without HSCT) for B-cell malignancies, Veto Cell kidney transplants, VETO CAR-T for solid tumors, Veto Cell liver transplants, and Veto HSCT for non-malignant disorders. The Company's wholly owned subsidiary is Cell Source Limited (CSL).
CELL SOURCE, INC. 
